Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Sprout Social

NEW YORK, July 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=89100&wire=1 or contact Joseph E. Levi, Esq.

Teladoc Health, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - TDOC

NEW YORK , July 3, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the "Class Period"), of the important July 16, 2024 lead plaintiff deadline. So what: If you purchased Teladoc stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Teladoc Health, Inc. Sued for Securities Law Violations - Contact the Rosen Law Firm Before July 16, 2024 to Discuss Your Rights - TDOC

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Teladoc To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Teladoc stock or options between November 2, 2022 and February 20, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TDOC.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Teladoc

Teladoc Health, Inc. faces an internal crisis with stock at all-time lows and a new CEO. The company has massive opportunities in weight loss management, but the focus appears more on telesales and digital advertising over product innovation. Teladoc Health stock trades at a cheap valuation with potential for multiple expansion, if the new CEO drives product innovation.

Teladoc Health: Weight Loss Management Could Help

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC).

Teladoc Health, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 16, 2024 to Discuss Your Rights – TDOC

NEW YORK , July 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Teladoc investors who were adversely affected by alleged securities fraud between November 2, 2022 and February 20, 2024.

Lost Money on Teladoc Health, Inc. (TDOC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=88432&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Teladoc Health, Inc. (TDOC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

SAN DIEGO, June 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of shares of Teladoc Health, Inc. (NYSE: TDOC) stock between November 2, 2022 and February 20, 2024, all dates inclusive (the “Class Period”), have until Tuesday, July 16, 2024 to seek appointment as lead plaintiff of the Teladoc class action lawsuit. Captioned Stary v. Teladoc Health, Inc., No. 24-cv-03849 (S.D.N.Y.), the Teladoc class action lawsuit charges Teladoc as well as certain of Teladoc's top current and former executives with violations of the Securities Exchange Act of 1934.

TDOC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Teladoc Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

ROSEN, A TOP RANKED LAW FIRM, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

NEW YORK , June 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC). Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders of Teladoc Health, Inc. Should Contact The Gross Law Firm Before July 16, 2024 to Discuss Your Rights - TDOC

Teladoc (TDOC) closed at $10.14 in the latest trading session, marking a -0.1% move from the prior day.

Teladoc (TDOC) Stock Declines While Market Improves: Some Information for Investors

SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Teladoc Health, Inc. (NYSE: TDOC) common stock between November 2, 2022 and February 20, 2024. Teladoc provides direct-to-consumer, online health services.

TDOC Lead Plaintiff Deadline Approaching - Stockholders Should Contact Robbins LLP for Information

RingCentral

Block

Uncovering growth stocks with long-term potential is vital for investors trying to assemble strong portfolios in the current market environment. These seven long-term growth stocks show businesses with creative plans and solid fundamentals ready to outperform.

7 Must-Have Growth Stocks to Hold Until 2031

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=87608&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by July 16, 2024 Deadline to Join Class Action Against Teladoc Health, Inc.(TDOC)

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=87562&wire=1 or contact Joseph E. Levi, Esq.

Teladoc Health, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 16, 2024 to Discuss Your Rights - TDOC

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Teladoc Health

NEW YORK , June 26, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Teladoc investors who were adversely affected by alleged securities fraud between November 2, 2022 and February 20, 2024.

Teladoc Health, Inc. Class Action: Levi & Korsinsky Reminds Teladoc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 16, 2024 - TDOC

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=87496&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Teladoc Health, Inc.(TDOC) should contact Levi & Korsinsky about pending Class Action - TDOC

NEW YORK , June 25, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the "Class Period"), of the important July 16, 2024 lead plaintiff deadline. So what: If you purchased Teladoc stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Teladoc Health, Inc. Sued for Securities Law Violations - Investors Should Contact The Rosen Law Firm Before July 16, 2024 to Discuss Your Rights - TDOC

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the July 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities during the period of November 2, 2022 through February 20, 2024, inclusive (“the Class Period”). Investors have until July 16, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

TDOC INVESTOR ALERT: Kirby McInerney LLP Notifies Teladoc Health, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%

Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?

NEW YORK , June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC). Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Teladoc Health, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 16, 2024 - TDOC

NEW YORK, NY / ACCESSWIRE / June 24, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=87211&wire=1 or contact Joseph E. Levi, Esq.

News for Teladoc Stock (TDOC)